T. Ibrahim

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
T Ibrahim, T. Ibrahim, Toni Ibrahim
Publication record
278 papers · 7,632 citations · H-index 44

PAPERS

Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours.
20238 citationsauthor #11
HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors
20234 citationsauthor #3
Osteogenic sarcomas of the hands: A case series with emphasis in its peculiarities and literature review.
20230 citationsauthor #8
Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin
202331 citationsauthor #18
Ipilimumab and nivolumab: the 'new kid on the block' in advanced angiosarcoma.
20231 citationsauthor #3
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial
20231 citationsauthor #6
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)
20238 citationsauthor #10
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis
20226 citationsauthor #14
Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing
20223 citationsauthor #7
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study
202219 citationsauthor #5
Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches
202229 citationsauthor #14
A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences
202245 citationsauthor #14
177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials
20228 citationsauthor #3
A Modular Composite Device of Poly(Ethylene Oxide)/Poly(Butylene Terephthalate) (PEOT/PBT) Nanofibers and Gelatin as a Dual Drug Delivery System for Local Therapy of Soft Tissue Tumors
202218 citationsauthor #8
The emerging role of cancer nanotechnology in the panorama of sarcoma
202226 citationsauthor #14
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms
202268 citationsauthor #8
Spine high-grade osteosarcoma in the era of radiotherapy with high-energy charged particles: A single institution retrospective analysis.
20221 citationsauthor #7
Phase 2 study for nonmetastatic extremity high‐grade osteosarcoma in pediatric and adolescent and young adult patients with a risk‐adapted strategy based on ABCB1/P‐glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS‐2)
202229 citationsauthor #26
Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives
202263 citationsauthor #16
HRAS expression predicts Lenvatinib responsiveness in human primary gastroenteropancreatic neuroendocrine tumor cells.
20220 citationsauthor #19
Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy
202226 citationsauthor #20
Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study
20227 citationsauthor #15
3-T magnetic resonance–guided high-intensity focused ultrasound (3 T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors
202217 citationsauthor #20
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis
202211 citationsauthor #21
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
202254 citationsauthor #4
Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): Results of a phase 2 study from Italian sarcoma group (ISG).
20221 citationsauthor #8
Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients
202118 citationsauthor #23
Dendritic cell vaccines manufacturing for treatment of cancer patients: a 11-year product quality control test collection of an advanced therapy medicinal product and compliance with the good manufacturing practices guideline
20210 citationsauthor #12
Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention
202134 citationsauthor #7
Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
202120 citationsauthor #6
Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
202125 citationsauthor #11
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
202134 citationsauthor #15
ALK-negative lung inflammatory myofibroblastic tumor in a young adult
20219 citationsauthor #11
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group
202123 citationsauthor #14
The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient‐derived primary culture case series in tridimensional and zebrafish models
202146 citationsauthor #23
First prospective data on breast cancer patients from the multicentre italian bone metastasis database
20218 citationsauthor #17
Potency Assessment of Dendritic Cell Anticancer Vaccine: Validation of the Co-Flow DC Assay
20216 citationsauthor #7
1097O The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs
202115 citationsauthor #12
Perfusion Flow Enhances Viability and Migratory Phenotype in 3D-Cultured Breast Cancer Cells
202126 citationsauthor #7
381TiP Vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma: A phase II study (CombiGVax)
20210 citationsauthor #20
Acid-Induced Inflammatory Cytokines in Osteoblasts: A Guided Path to Osteolysis in Bone Metastasis
202113 citationsauthor #5
Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms
202139 citationsauthor #14
1296P Immune checkpoint inhibitors with or without bone targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio
20210 citationsauthor #19
Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas
202133 citationsauthor #16
A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107).
202128 citationsauthor #12
Abstract 2776: Sequential immunohistochemistry and computational image analysis for a deeper characterization of tumor-infiltrating myeloid cells
20210 citationsauthor #11
Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas
202126 citationsauthor #25
Identification of a novel RAB3IP-HMGA2 fusion transcript in an adult head and neck rhabdomyosarcoma.
202116 citationsauthor #21
Tamoxifen protects breast cancer patients from COVID-19: first evidence from real world data
20215 citationsauthor #23
Development and validation of an in-silico tool for the study of therapeutic agents in 3D cell cultures
20218 citationsauthor #4
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
202176 citationsauthor #29
Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).
20211 citationsauthor #5
Induction Chemotherapy plus Concomitant Chemoradiotherapy in Nasopharyngeal Carcinoma: an Updated Network Meta-Analysis.
202123 citationsauthor #8
Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
202151 citationsauthor #14
Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells
20219 citationsauthor #15
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors
202154 citationsauthor #6
Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion
202028 citationsauthor #6
1161MO Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results
202011 citationsauthor #5
Abstract 333: Development of a biomimetic 3D scaffold to study breast cancer bone metastasis
20200 citationsauthor #17
Prognostic role of pre-treatment magnetic resonance imaging (MRI) radiomic analysis in patients with squamous cell carcinoma of the head and neck (SCCHN).
20200 citationsauthor #14
Comment on ‘Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: A nationwide Italian survey’ by Alice Indini et al.
20205 citationsauthor #4
Trends in Bone Metastasis Modeling
202014 citationsauthor #3
The potential role of extracellular matrix in the activity of trabectedin.
20200 citationsauthor #15
CAR T cells targeting options in the fight against multiple myeloma.
20204 citationsauthor #8
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study
202028 citationsauthor #5
Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group
20208 citationsauthor #21
Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group
202052 citationsauthor #21
Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review
202041 citationsauthor #5
1169P First-line fluoropyrimidine and oxaliplatin chemotherapy in gastro-entero-pancreatic grade 3 well-differentiated neuroendocrine tumours (NET G3)
20202 citationsauthor #3
Abstract 260: Bromodomain and extra-terminal motif proteins regulate linear and circular PVT1 in acute myeloid leukemia cells under normoxia and hypoxia
20200 citationsauthor #9
Lineage‐specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture
202018 citationsauthor #15
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study
202043 citationsauthor #10
First-line fluoropyrimidine and oxaliplatin chemotherapy in gastro-entero-pancreatic grade III well-differentiated neuroendocrine tumors (NET G3).
20202 citationsauthor #3
Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary.
202015 citationsauthor #6
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review
20207 citationsauthor #6
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer
202033 citationsauthor #6
Editorial: New Insights Into the Landscape of Rare Tumors: Translational and Clinical Research Perspective
20200 citationsauthor #4
Correlation of DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms with loss of RB1 and prognostic significance.
20201 citationsauthor #13
Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
20208 citationsauthor #3
Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma
20208 citationsauthor #7
Establishment of a primary cell culture of bone metastasis from urothelial carcinoma.
20200 citationsauthor #13
Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis
202030 citationsauthor #13
Familial adenomatosis polyposis–related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis
202019 citationsauthor #8
A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib.
202068 citationsauthor #17
Multicenter Italian bone metastasis database: First prospective data on breast cancer patients.
20200 citationsauthor #20
Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis
20204 citationsauthor #9
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A “Real-World” Data Analysis
202029 citationsauthor #13
Trefoil Factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis.
202016 citationsauthor #14
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol
202015 citationsauthor #16
An in-silico study of cancer cell survival and spatial distribution within a 3D microenvironment
202020 citationsauthor #4
Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group
202024 citationsauthor #4
Computational models to explore the complexity of the epithelial to mesenchymal transition in cancer
202011 citationsauthor #4
Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis
202015 citationsauthor #14
mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model
20199 citationsauthor #9
Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
201978 citationsauthor #8
First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
20197 citationsauthor #3
Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events
201919 citationsauthor #12
Non-conventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor.
201940 citationsauthor #5
Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs): A pooled analysis of two phase II trials with pazopanib and lenvatinib.
20193 citationsauthor #4
BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study)
20197 citationsauthor #17

TIMELINE

2002 57 citations

2003 7 citations

2004 0 citations

2005 33 citations

2007 1 citations

2008 70 citations

2009 51 citations

2010 218 citations

2011 726 citations

2012 1,231 citations

2013 1,257 citations

2014 407 citations

2015 472 citations

2016 298 citations

2017 442 citations

2018 179 citations

2019 399 citations

2020 579 citations

2021 646 citations

2022 431 citations

2023 53 citations

Unknown 85 citations

T. Ibrahim

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT